Publications by authors named "Geke C Poolen"
Background: Venous thromboembolism (VTE) can recur shortly after stopping anticoagulation, highlighting the need for reliable biomarkers to identify high-risk patients during treatment.
Objectives: To determine whether platelet and endothelial markers predict VTE recurrence.
Methods: We used data and samples from the randomized controlled VISTA trial (2011-2015), which included patients with unprovoked VTE who were treated with vitamin K antagonists for 6 months.
Article Synopsis
- Thrombopoietin receptor agonists, like eltrombopag, are commonly used to treat immune thrombocytopenia (ITP) due to their effectiveness and tolerability, although there's concern about the risk of thrombosis.
- A study was conducted to evaluate how ITP patients respond to eltrombopag in terms of platelet function and hypercoagulability, comparing results from patients to healthy controls.
- Findings revealed that ITP patients were in a hypercoagulable state with altered platelet activity, and while eltrombopag treatment increased thrombin generation potential, these changes were not statistically significant after correction for multiple comparisons.
Background: Thrombomodulin on endothelial cells can form a complex with thrombin. This complex has both anticoagulant properties, by activating protein C, and clot-protective properties, by activating thrombin-activatable fibrinolysis inhibitor (TAFI). Activated TAFI (TAFIa) inhibits plasmin-mediated fibrinolysis.
View Article and Find Full Text PDF